We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Effect of (des-Tyr1)-γ-endorphin on Prolactin Secretion

Herbert Y. Meltzer, MD; Daniel A. Busch, MD; Paul M. Schyve, MD; Victor S. Fang, MD
Arch Gen Psychiatry. 1981;38(10):1183. doi:10.1001/archpsyc.1981.01780350117014.
Text Size: A A A
Published online


To the Editor.—  Verhoeven and colleagues (Archives 1979;36:294-298) have reported that (des-Tyr1)-γ-endorphin (DTγE; β-lipotropin62-77) has antipsychotic properties in some schizophrenic patients, but this was not replicated in two recent studies.1.2 Animal experiments have suggested that DTγE may have direct or indirect neuroleptic properties. Neuroleptics are potent stimulants of prolactin secretion in the rat; most neuroleptics, with the exception of clozapine and melperone, are also potent stimulants of prolactin secretion at therapeutic dosages in man.3 (Des-Tyr1)-γ-endorphin has been identified in the pituitary of man and the rat.4 We were interested in determining the effect of DTγE on prolactin secretion in man and laboratory rats.

Subjects and Methods.—  We have now treated four male schizophrenic patients (diagnosis by Research Diagnostic Criteria) with intramuscular injections of DTγE in dosages of 1 to 10 mg/day. All were admitted because of a recent exacerbation of their psychoses. Dosages greater


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.